These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 18477663)

  • 1. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
    Freda PU; Katznelson L; van der Lely AJ; Reyes CM; Zhao S; Rabinowitz D
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4465-73. PubMed ID: 15886238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
    Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
    Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on lanreotide Autogel in acromegaly.
    Croxtall JD; Scott LJ
    BioDrugs; 2008; 22(4):275-7. PubMed ID: 18611070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
    Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
    Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
    Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of lanreotide and octreotide LAR for treatment of acromegaly.
    Turner HE; Vadivale A; Keenan J; Wass JA
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):275-80. PubMed ID: 10469005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China].
    Xuan JW; Zhang ZY; Wang YF; Mao ZG; Lu YJ; Wang RZ
    Zhonghua Yi Xue Za Zhi; 2017 Mar; 97(10):765-769. PubMed ID: 28316158
    [No Abstract]   [Full Text] [Related]  

  • 16. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
    Turner HE; Lindsell DR; Vadivale A; Thillainayagam AV; Wass JA
    Eur J Endocrinol; 1999 Dec; 141(6):590-4. PubMed ID: 10601961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
    Alquraini H; Del Pilar Schneider M; Mirakhur B; Barkan A
    Pituitary; 2018 Jun; 21(3):283-289. PubMed ID: 29357081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.
    Ashwell SG; Bevan JS; Edwards OM; Harris MM; Holmes C; Middleton MA; James RA
    Eur J Endocrinol; 2004 Apr; 150(4):473-80. PubMed ID: 15080776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
    Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
    Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.